Global Overactive Bladder Therapeutics Market

1. Summary

The Global Overactive Bladder Therapeutics Market was valued at $4.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.8% CAGR, to an estimated market size of $5.1 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The Overactive Bladder (OAB) Therapeutics market encompasses the global landscape of pharmacological treatments (including anticholinergics and beta-3 adrenergic agonists), minimally invasive procedures (such as botulinum toxin injections and neuromodulation), and behavioral interventions designed to manage symptoms of urinary urgency, frequency, and urge incontinence. The scope includes both idiopathic and neurogenic bladder overactivity but excludes major reconstructive urological surgeries.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Overactive Bladder Therapeutics Market in the period 2025-30:

• The rapidly aging global population is the primary driver, as OAB prevalence increases significantly in individuals over the age of 65.
• There is a growing shift toward combination therapies, specifically pairing anticholinergics with beta-3 adrenergic agonists to maximize efficacy while reducing side effects.
• Advancements in minimally invasive neuromodulation, such as sacral and posterior tibial nerve stimulation, are gaining traction as preferred third-line treatments.
• The integration of digital health tools, including mobile apps for bladder diaries and wearable sensors, is improving patient adherence and data-driven management.
• Rising prevalence of comorbid conditions such as diabetes, obesity, and neurological disorders like Parkinson’s is expanding the addressable patient pool.
• Increased public awareness campaigns and the expansion of telehealth are reducing the social stigma associated with OAB, leading to higher diagnosis rates.
• A robust R&D pipeline focusing on novel delivery systems and emerging gene therapies is expected to introduce more targeted treatment options by 2030.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: